Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns 

(Bloomberg) -- French drugmaker Ipsen SA had a record plunge after U.S. regulators suspended trials of its experimental treatment for rare bone diseases in patients under 14 on safety concerns.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.